| Primary information |
|---|
| sequence ID | Seq_1201 |
| Peptide sequence | DEAGSEADHEGTHSTKR |
| CancerPDF_ID | CancerPDF_ID1243, CancerPDF_ID9683, CancerPDF_ID10335, |
| PMID | 21136997,21533267,21805675 |
| Protein Name | Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Serum,Serum,Urine |
| M/Z | 1825.7827,609.6,1826.7841 |
| Charge | 1,3,NA |
| Mass (in Da) | NA,NA,NA |
| fdr | NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,MALDI-TOF |
| Peptide Identification technique | LC-MS-MS/MS,LC/MS/MS,MALDI-TOF-MS |
| Quantification Technique | LC-ESI-MS,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | NA,1.49,1 |
| CancerPDF_ID | CancerPDF_ID1243, CancerPDF_ID9683, CancerPDF_ID10335, |
| p-Value | NA,NA,NA |
| Software | MASCOT(v. 2.2.01),MASCOT,NA |
| Length | 17,17,17 |
| Cancer Type | Colorectal cancer,Lung adenocarcinoma,Muscle-invasive bladder cancer |
| Database | SwissProt Database,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA |
| Number of Patients | 30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control,751 bladder cancer and 127 control |
| Regulation | NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal",Differentially expressed between cancer vs normal samples |
| Validation | Leave One out Cross validation,MRM-based validation of 19 candidates,Mann-Whitney tests and areas under receiver-operator characteristic |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |